Company Information

  

Address: 9635 GRANITE RIDGE DRIVE, SUITE 100  
City: SAN DIEGO 
State: CA 
Zip Code: 92123 
Telephone: 858-459-7800 

Description of Business

Primary SIC Code: 3826
(As filed with the SEC)  

We are a medical technology company focused on addressing unmet needs in global health and biodefense. The Aethlon Hemopurifier® is a clinical-stage therapeutic device designed for the single-use removal of life-threatening viruses from the circulatory system of infected individuals. We believe the Hemopurifier® can fulfill the broad-spectrum countermeasure objectives set forth by the U.S. Government to protect citizens from bioterror and pandemic threats. In human studies, the Hemopurifier® has been administered to HIV, Hepatitis-C and Ebola infected individuals. Additionally, the Hemopurifier® has also been validated to capture Zika virus, Lassa virus, MERS-CoV, Cytomegalovirus, Epstein-Barr virus, Herpes Simplex virus, Chikungunya virus, Dengue virus, West Nile virus, Smallpox related viruses, H1N1 Swine Flu virus, H5N1 Bird Flu virus, and the reconstructed Spanish flu virus of 1918.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-0.87NAN/E
03/2017-0.94NAN/E
12/2016-0.88NAN/E
09/2016-0.89NAN/E
06/2016-0.76NAN/E
03/2016-0.66NAN/E
12/2015-0.60NAN/E
09/2015-0.64NAN/E

Key Financial Ratios and Statistics

FYE: 03/31

Profitability 2017 Leverage 2017
Net Inc/Comm Equity-0.08Total Liab/Total Assets0.61
Net Inc/Total Assets-4.21Total Liab/Inv Cap0.94
Net Inc/Inv Cap-6.53Total Liab/Comm Equity0.01
Pretax Inc/Net Sales-18.64Interest Coverage Ratio-23.01
Net Inc/Net Sales-18.56Curr Debt/EquityNA
Cash Flow/Net Sales-8.94LTD/Equity0.77
SG&A/NetSales16.55Total Debt/Equity0.77
Asset Utilization   Liquidity  
Net Receivables Turnover3.93Quick Ratio2.61
Inventory TurnoverNACurrent Ratio2.61
Inventory Day SalesNANet Rec/Curr AssetsNA
Net Sales/Work Cap0.40Inv/Curr AssetsNA
Net Sales/PP&E13.42  

Income Statement (Millions)

  6/30/2017 3/31/2017 12/31/2016 9/30/2016
Total Revenues(Net Sales) 0.00 0.00 0.00 0.39
Cost of Goods Sold NA NA NA NA
Selling & Admin Exps 1.16 1.50 1.24 2.61
Operating Income -1.16 -1.50 -1.24 -2.23
Interest Exp 0.19 0.19 0.04 0.04
Pretax Income -1.85 -1.69 -1.21 -2.26
Other Income -0.50 0.00 0.06 0.00
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -1.84 -1.69 -1.21 -2.26

Balance Sheet (Millions)

Assets 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Cash & Short Term Investments 0.33 1.56 0.63 0.56
Receivables - Total NA 0.00 0.00 0.19
Inventories - Total NA NA NA NA
Total Current Assets 0.37 1.60 0.66 0.82
Net Property, Plant & Equipment 0.05 0.03 0.02 0.02
Total Assets 0.51 1.73 0.79 0.95
Liabilities        
Accounts Payable 0.33 0.54 0.35 0.44
Debt in Current Liabilities NA NA NA 0.61
Total Current Liabilities 0.41 0.61 0.37 1.08
Long-Term Debt 1.05 0.52 0.41 0.00
Total Liabilities 1.37 1.05 0.72 1.02
Stockholder's Equity        
Minority Interest -0.08 -0.08 -0.07 -0.07
Preferred Stock NA NA NA NA
Common Stock 0.01 0.01 0.01 0.01
Retained Earnings -95.62 -93.78 -92.09 -90.89
Treasury Stock NA NA NA NA
Total Stockholders' Equity -0.87 0.68 0.07 -0.07
Total Liabilities and Stockholders' Equity 0.51 1.73 0.79 0.95

Cash Flow Summary (Millions)

Categories 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Net Cash Provided by Operating Activities -1.07 -0.95 -0.79 -0.94
Net Cash Provided by Investing Activities -0.02 -0.01 0.00 -0.00
Net Cash Provided by Financing Activities -0.13 1.90 0.86 0.20

Annual Summary Data (Millions)

Year Sales Net Income EPS
03/20131.23-4.89--
03/20141.62-13.36--
03/20150.76-6.80--
03/20160.89-4.87-0.66
03/20170.39-7.28-0.94
Growth Rates-24.86----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17162041.36




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.